Application

Analytes: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1) Recommended Sample Type: Human serum, plasma, and tissue/cell culture supernatants or lysates Recommended Sample Dilution: 25 µL of 1:10 diluted serum or plasma; tissue/cell culture supernatants or lysates diluted may be diluted as needed in appropriate control medium Assay Run Time: Overnight (16-18 hours) at 2-8°C Research Category: Cancer

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

General description

The MILLIPLEX^®Human Cancer/Metastasis Biomarker Panel 1 contains nine metastasis biomarkers that have also been identified in a variety of tumor types. Coupled with the Luminex^® xMAP^® platform in bead format, this panel enables researchers to focus on discovery with the advantage of simultaneous quantitative multiplex detection leading to speed and sensitivity. Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors. Panel Type: Circulating Cancer

Legal Information

xMAP is a registered trademark of Luminex Corp

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.